News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

The Aladote study in patients treated for paracetamol overdose proceeds into final dosage group

February 1, 2018


After completion of recruitment of the second dosage cohort and review by the data safety monitoring committee, the approval was given to initiate the 3rd and last cohort in the open-label, randomised, rising dose design, proof-of-principle safety and tolerability study with Aladote in patients treated with NAC for paracetamol overdose.

The study is conducted at the University of Edinburgh, Queen’s Medical Research Institute in Scotland and will involve a total of 24 patients assigned into one of 3 dosing cohorts of 8 patients.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10